Allied Patients has launched to develop affordable generic medications and do right by patients.
"Patients are suffering, and medical insurance companies are paying more for healthcare because of unreasonable medication price increases. It's time for things to change," said Eduardo Matto, MD, CEO and Founder of Allied Patients
Currently, there are over 500 branded medications without a generic alternative, and monopolies drive unnecessary price increases. Older branded medications no longer cost manufacturers money for research and development, yet certain products have increased in price as much as 2,500% in the last three years alone.
With pharmaceutical sales at $333 billion per year and rising and traditional generic companies are unable to quickly develop low-volume, high-need medications because of consolidation in the industry.
Allied Patients seeks to streamline the way medications are produced and distributed, reducing the red tape and price barriers between patients and the treatments they need. The company relies on a distributed development and manufacturing network that can develop a generic medication and complete bioequivalence study in 12 months. All development work and bioequivalence studies are done in the United States to ensure FDA regulations are met and direct quality monitoring throughout the process.